Table 2 aFXa and outcomes for patients with critical COVID-19 admitted from March 2020 to May 2021 to ICUs at the participating hospitals with no diagnosis of TE or major bleed at admission

No of aFXa during ICU stay per patient, median (IQR)

-

1 (1 to 3)

2 (1 to 3)

aFXa, minimum value during ICU stay, median (IQR), kIU/L

-

0.41 (0.29 to 0.55)

0.21 (0.14 to 0.34)

aFXa, median value over the first 14 ICU days, median (IQR), kIU/L

-

(n = 126)

0.5 (0.34 to 0.64)

(n = 266)

0.29 (0.21 to 0.46)

aFXa, maximum value during ICU stay, median (IQR), kIU/L

-

0.55 (0.39 to 0.76)

0.38 (0.24 to 0.56)

Days in ICU, median (IQR)

11 (5 to 22)

19 (13 to 30)

17 (9 to 28)

Death within 90 days

314 (27.5)

55 (35.9)

95 (31.7)

Death in ICU

258 (22.6)

49 (32.0)

88 (29.3)

Any thromboembolism and/or bleeding

378 (33.2)

57 (37.3)

117 (39.0)

Thromboembolism

160 (14.0)

17 (11.1)

37 (12.3)

 Pulmonary embolism/thrombosis^a

134 (11.8)

14 (9.2)

31 (10.3)

 Deep venous thrombosis^b

32 (2.8)

3 (2.0)

5 (1.7)

 Ischemic stroke^a

11 (1.0)

2 (1.3)

3 (1.0)

Bleeding^c

288 (25.2)

48 (31.3)

100 (33.3)

Major bleeding^d

72 (6.3)

15 (9.8)

23 (7.7)